Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairm ...